BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 14872478)

  • 1. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.
    Wolfe F; Michaud K; Anderson J; Urbansky K
    Arthritis Rheum; 2004 Feb; 50(2):372-9. PubMed ID: 14872478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
    Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
    J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
    Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
    Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
    Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Romanus V; Klareskog L; Feltelius N
    Arthritis Rheum; 2005 Jul; 52(7):1986-92. PubMed ID: 15986370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F; Michaud K
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population.
    Ponce de Leon D; Acevedo-Vasquez E; Alvizuri S; Gutierrez C; Cucho M; Alfaro J; Perich R; Sanchez-Torres A; Pastor C; Sanchez-Schwartz C; Medina M; Gamboa R; Ugarte M
    J Rheumatol; 2008 May; 35(5):776-81. PubMed ID: 18398944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis.
    Stern R; Wolfe F
    J Rheumatol; 2004 Aug; 31(8):1538-45. PubMed ID: 15290732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada.
    Brassard P; Lowe AM; Bernatsky S; Kezouh A; Suissa S
    Arthritis Rheum; 2009 Mar; 61(3):300-4. PubMed ID: 19248128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
    Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
    Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
    Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.
    Mohan AK; Coté TR; Block JA; Manadan AM; Siegel JN; Braun MM
    Clin Infect Dis; 2004 Aug; 39(3):295-9. PubMed ID: 15306993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.
    Menter A; Reich K; Gottlieb AB; Bala M; Li S; Hsu MC; Guzzo C; Diels J; Gelfand JM
    J Drugs Dermatol; 2008 Dec; 7(12):1137-46. PubMed ID: 19137767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of tuberculosis in patients with rheumatoid arthritis.
    Carmona L; Hernández-García C; Vadillo C; Pato E; Balsa A; González-Alvaro I; Belmonte MA; Tena X; Sanmartí R;
    J Rheumatol; 2003 Jul; 30(7):1436-9. PubMed ID: 12858438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab therapy in established rheumatoid arthritis: an observational study.
    Voulgari PV; Alamanos Y; Nikas SN; Bougias DV; Temekonidis TI; Drosos AA
    Am J Med; 2005 May; 118(5):515-20. PubMed ID: 15866254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E; Tanaff P; Mariotte D; Costentin-Pignol V; Marcelli C; Ballet JJ
    J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Symmons DP; Watson KD; Silman AJ;
    Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
    Wolfe F; Michaud K
    Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antirheumatic drugs and the risk of tuberculosis.
    Brassard P; Kezouh A; Suissa S
    Clin Infect Dis; 2006 Sep; 43(6):717-22. PubMed ID: 16912945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low prevalence of reactive PPD prior to infliximab use: comparative study on a population sample of Hospital Geral de Fortaleza.
    Callado MR; Lima JR; Nobre CA; Vieira WP
    Rev Bras Reumatol; 2011; 51(1):40-52. PubMed ID: 21412605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions.
    Shatin D; Rawson NS; Curtis JR; Braun MM; Martin CK; Moreland LW; Becker AF; Patkar NM; Allison JJ; Saag KG
    Pharmacoepidemiol Drug Saf; 2006 Jan; 15(1):11-8. PubMed ID: 16136625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.